An interview with a US-based key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Idhifa, Tibsovo, magrolimab, quizartinib, crenolanib, gilteritinib, and uproleselan.
Acute Myeloid Leukemia (AML) in the United States: Key Insights into Treatment Awareness & Satisfaction
- Report
- 45 Pages
- United States
